ScripThe case for the US Food and Drug Administration to make Merck & Co., Inc. and Daiichi Sankyo Co., Ltd. ’s HER3-targeting antibody-drug conjugate (ADC) patritumab deruxtecan the first anti-HER3 ADC
ScripBioNTech and MediLink Therapeutics will resume enrolment in a Phase I study of their antibody-drug conjugate, BNT326, in lung and breast cancer patients after a partial hold related to treatment-rela
ScripEisai Co., Ltd. ’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisa
Pink SheetChina has broken its own record for the number of clinical trial registrations in one year, with the total surging by 26% in 2023 to reach 4,300, notes a new annual report from the country's Center fo